226 related articles for article (PubMed ID: 10869410)
1. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
[TBL] [Abstract][Full Text] [Related]
2. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
3. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
[TBL] [Abstract][Full Text] [Related]
4. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
[TBL] [Abstract][Full Text] [Related]
5. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
6. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.
Millan MJ; Dekeyne A; Rivet JM; Dubuffet T; Lavielle G; Brocco M
J Pharmacol Exp Ther; 2000 Jun; 293(3):1063-73. PubMed ID: 10869411
[TBL] [Abstract][Full Text] [Related]
7. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
[TBL] [Abstract][Full Text] [Related]
8. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
9. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.
Millan MJ; Seguin L; Gobert A; Cussac D; Brocco M
Psychopharmacology (Berl); 2004 Jul; 174(3):341-57. PubMed ID: 14985929
[TBL] [Abstract][Full Text] [Related]
10. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
[TBL] [Abstract][Full Text] [Related]
11. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
12. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
13. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
Loiseau F; Millan MJ
Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
[TBL] [Abstract][Full Text] [Related]
14. The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
Cussac D; Newman-Tancredi A; Sezgin L; Millan MJ
Eur J Pharmacol; 2000 Apr; 394(1):47-50. PubMed ID: 10771033
[TBL] [Abstract][Full Text] [Related]
15. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
16. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
[TBL] [Abstract][Full Text] [Related]
17. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
Millan MJ; Girardon S; Monneyron S; Dekeyne A
Neuropharmacology; 2000 Feb; 39(4):586-98. PubMed ID: 10728880
[TBL] [Abstract][Full Text] [Related]
19. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.
Millan MJ; Di Cara B; Dekeyne A; Panayi F; De Groote L; Sicard D; Cistarelli L; Billiras R; Gobert A
J Neurochem; 2007 Feb; 100(4):1047-61. PubMed ID: 17266737
[TBL] [Abstract][Full Text] [Related]
20. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]